Substrate for CYP 3A4. Conflicting evidence of porphyrinogenicity.

(To be edited, initial data ST OCT 04) 4-azasteroide used in prostatic hypertrophy, 5 mg/d Competetive inhibitor of 5-alpha reductase which converts testosterone to the more potent androgen dihydroform needed for the growth of the prostatic tissue. Metabolized by 3A4. South African list: use with extreme caution only. French list: authorized

Uneventful use reported in 3 patients with acute porphyria.